Sulzer Hip, Knee Surgery Patients Would Be Compensated By Profits, Insurer
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Medica is proposing to use one-half of its annual net income to help finance a nearly $100,000 cash-and-equity compensation package for hip-and-knee implant patients requiring multiple revision surgeries over the next three to five years.
You may also be interested in...
Sulzer Medica Inter-Op Settlement Results In $546 Mil. Charge For Q2
Nearly 70% of a $783 mil. proposed settlement for Sulzer Medica's Inter-Op hip recall and withdrawn tibial baseplates is being booked in the firm's second quarter, results for which were announced Sept. 19.
Sulzer Medica Inter-Op Settlement Results In $546 Mil. Charge For Q2
Nearly 70% of a $783 mil. proposed settlement for Sulzer Medica's Inter-Op hip recall and withdrawn tibial baseplates is being booked in the firm's second quarter, results for which were announced Sept. 19.
Inter-Op Settlement Stays $15.5 Mil. In Damages; State Plaintiffs Appeal
Sulzer Medica is relying on an anticipated class settlement to impose a seven-year freeze on hip and knee revision damages already being awarded at the state court level.